StockNews.AI
BMRA
StockNews.AI
2 days

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use

1. Biomerica's Fortel® Kidney Test approved for home use in UAE. 2. The test detects early kidney damage, crucial for diabetes and hypertension patients. 3. High diabetes (1 in 4) and hypertension (31% overall) rates in the UAE noted. 4. The approval enhances Biomerica's presence in the Middle East healthcare market. 5. Fortel® Test addresses CKD burden, a global health concern affecting millions.

8m saved
Insight
Article

FAQ

Why Bullish?

The approval of the Fortel® Kidney Test may enhance Biomerica's revenue streams, similar to past product launches that drove stock prices up.

How important is it?

The regulatory approval signifies a potential shift in market dynamics for Biomerica, likely increasing sales and investor confidence.

Why Short Term?

Positive market sentiment may be seen quickly with product rollout in pharmacies and clinics.

Related Companies

ABTDGXLH
10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early identification of kidney damage in high-risk populations. The Fortel® Kidney Test is a rapid, 10-minute easy to use diagnostic test that detects low levels of albumin in urine, a critical early marker of kidney disease. The test is particularly valuable for people living with diabetes and hypertension, two of the leading risk factors for chronic kidney disease (CKD). Early detection provides an opportunity for timely medical intervention that can slow or prevent progression to kidney failure. Diabetes and Hypertension: Major Risk Factors in the UAE Diabetes affects approximately one in four UAE nationals, while a published meta-analysis found overall hypertension prevalence to be about 31%, with higher rates in men (43.9%) than women (34.5%). Both conditions are major contributors to CKD and often remain undiagnosed until significant kidney damage has occurred. “The Fortel® Kidney Test addresses a gap in preventative healthcare by allowing patients and physicians to detect kidney disease before symptoms appear,” said Zack Irani, CEO of Biomerica. “With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed.” Supporting Healthcare Access in the Middle East This approval strengthens Biomerica’s growing presence in the Middle East, following the regional success of its EZ Detect™ Colon Disease Test and other innovative diagnostic products. Through partnerships with leading distributors and healthcare providers, the Fortel® Kidney (Microalbumin) Test is planned available in pharmacies, clinics, and hospitals throughout the UAE. Global and Local Significance By aligning local initiative with global urgency, the Fortel® test addresses a window for intervention, at a time when CKD globally affects over 840 million people, is rising in prevalence, and continues to drive morbidity and mortality. In the UAE, where diabetes and hypertension are widespread, Fortel® enables accessible, patient-centered monitoring, positioning Biomerica to become a leader of preventive diagnostics in a high-need region while echoing the broader imperative to curtail the CKD burden worldwide. About Biomerica (NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company’s products and tests including the Fortel® Kidney Test, FDA and/or international regulatory authorization for the Company’s products to be marketed and sold, including the Fortel® Kidney Test, and the Company’s other current and future products, the possible expansion in to other markets, uniqueness of the Company’s products, accuracy of the Company’s tests and products, pricing of the Company’s test kits, domestic and/or international market adoption and acceptance and demand for the Company’s products including the Fortel® Kidney Test, the availability of product in pharmacies, clinics, and hospitals, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company’s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversite, and the Company’s ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release. Corporate Contact: Zack Irani | CEOp. 949.645.2111www.biomerica.com Source: Biomerica

Related News